Institutional implementation of clinical tumor profiling on an unselected cancer population.
about
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum.Managing the genomic revolution in cancer diagnostics.Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma.Oncologist use and perception of large panel next-generation tumor sequencing.Molecular diagnostics of lung cancer in the clinic.Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.Somatic mutations in CDH1 and CTNNB1 in primary carcinomas at 13 anatomic sites.Uterine inflammatory myofibroblastic tumor: more common than expected: Case report and review.Unique, dual-indexed sequencing adapters with UMIs effectively eliminate index cross-talk and significantly improve sensitivity of massively parallel sequencing.Interactive or static reports to guide clinical interpretation of cancer genomics.Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response.GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma.Functional precision cancer medicine-moving beyond pure genomics.Next-generation sequencing of cytologic preparations: An analysis of quality metrics.A system for detecting high impact-low frequency mutations in primary tumors and metastases.Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour.Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.Oncogenic Signaling Pathways in The Cancer Genome Atlas.Frameshift events predict anti-PD-1/L1 response in head and neck cancer.Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations.2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma.Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAImproved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer
P2860
Q36364110-A5108DF9-6FE8-449D-ACDB-59FA9AA3EF3FQ38700674-1446D4F3-C55E-4342-A9A4-A0BE87B31B95Q38714606-E2E8DE04-BD21-4973-B275-672D830A952CQ38798543-52AA2417-6F85-48DB-8E1B-9700464710A1Q39022637-AA8048AC-4CCA-43F7-A911-D8DB01369C29Q40040765-FFBA26FE-4833-4FA9-8D7F-9A18800CD765Q43690882-4AC3B92F-AFB3-4404-9F9A-579A2B89856EQ46071509-E4D0E6D0-CC2F-4D90-B5BB-480BA9549324Q47107732-9D2E73E6-CE67-42DB-98CC-E7FECF2FF9E3Q47138572-D4D66282-BBFE-4F56-903B-AC58868049B7Q47176729-3D919673-7326-4381-B596-AEF64F944255Q47190133-E44985CF-13B4-4EA2-980C-128D9DCDEB9DQ47214510-E50F8793-2C0E-48F2-BF04-1D8343D5E05AQ47660305-439C33A1-B319-4F56-A2B6-9B3A4941C2BEQ47676925-BB34A447-5C99-4A96-B02A-98493378F24CQ47836088-ECE98E07-23DD-4CC8-88D3-AAEC287A164EQ48013156-2C037400-B1FD-436B-A465-919EE3D5422CQ48094842-50A5E690-3C43-4DF6-AF23-388898B8904EQ48095098-7209D7D1-971C-4D49-AC37-371309B6FFFFQ48301818-AD948B88-26D1-461C-9796-E32083D956A2Q48507434-403C4578-6058-4852-9526-73DFF1186721Q50027091-8F6754A7-2146-45BA-AD48-C658FD310282Q51751201-F8D4A943-8F50-43C0-84FD-57653A8EFBAFQ52602404-0EE927AC-F12C-4DA6-B1E3-AA25D0121F25Q54269200-3CE96477-46AA-4A1A-9805-6F761BB84A4EQ55457466-7896797C-2B41-41C7-997F-E7F488B21CDDQ55715100-440C8A8C-994F-4C48-9904-F140B0AB76C9Q56890749-B1BE3366-CD47-422C-AFCB-AD770D80C75DQ58760723-3ACC9B37-2C7D-4C6D-9234-B92CC9696338
P2860
Institutional implementation of clinical tumor profiling on an unselected cancer population.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Institutional implementation o ...... unselected cancer population.
@en
Institutional implementation o ...... unselected cancer population.
@nl
type
label
Institutional implementation o ...... unselected cancer population.
@en
Institutional implementation o ...... unselected cancer population.
@nl
prefLabel
Institutional implementation o ...... unselected cancer population.
@en
Institutional implementation o ...... unselected cancer population.
@nl
P2093
P2860
P50
P1433
P1476
Institutional implementation o ...... unselected cancer population.
@en
P2093
Aaron R Thorner
Adrian M Dubuc
Alanna Church
Alice H Berger
Azra H Ligon
Barrett J Rollins
Bruce E Johnson
David J Kwiatkowski
Elizabeth P Garcia
Ethan Cerami
P2860
P304
P356
10.1172/JCI.INSIGHT.87062
P577
2016-11-17T00:00:00Z